Higher concentrations of certain phthalate metabolites are associated with adverse reproductive and pregnancy outcomes, as well as poor infant/child health outcomes. In non-pregnant populations, phthalate metabolite concentrations vary by race/ethnicity. Few studies have documented racial/ethnic differences between phthalate metabolite concentrations at multiple time points across the full-course of pregnancy. The objective of the study was to characterize the change in phthalate metabolite concentrations by race/ethnicity across multiple pregnancy time points. Women were participants in a prospectively collected pregnancy cohort who delivered at term (≥37 weeks) and had available urinary phthalate metabolite concentrations for ≥ 3 time points across full-term pregnancies (n = 350 women). We assessed urinary concentrations of eight phthalate metabolites that were log-transformed and specific gravity-adjusted. We evaluated the potential racial/ethnic differences in phthalate metabolite concentrations at baseline (median 10 weeks gestation) using ANOVA and across pregnancy using linear mixed models to calculate the percent change and 95% confidence intervals adjusted for sociodemographic and lifestyle factors. Almost 30% of the population were non-Hispanic black or Hispanic. With the exception of mono-(3-carboxypropyl) (MCPP) and di-ethylhexyl phthalate (DEHP) metabolites, baseline levels of phthalate metabolites were significantly higher in non-whites (Po 0.05). When evaluating patterns by race/ethnicity, mono-ethyl phthalate (MEP) and MCPP had significant percent changes across pregnancy. MEP was higher in Hispanics at baseline and decreased in mid-pregnancy but increased in late pregnancy for non-Hispanic blacks. MCPP was substantially higher in non-Hispanic blacks at baseline but decreased later in pregnancy. Across pregnancy, non-Hispanic black and Hispanic women had higher concentrations of certain phthalate metabolites. These differences may have implications for racial/ ethnic differences in adverse pregnancy and child health outcomes.
INTRODUCTION
A growing body of evidence suggests that exposures to certain environmental chemicals during pregnancy, such as orthophthalates, may affect the short-and long-term health of both mothers and their offspring. [1] [2] [3] [4] [5] [6] Phthalates may be a particularly important class of environmental toxicants, given their ability to modulate hormone levels 7 and bind to nuclear receptors known as peroxisome proliferator-activated receptors. 8, 9 These chemicals are used in the production of a variety of consumer products, such as plasticizers, solvents, stabilizers, and lubricants. 8 They can be ingested, inhaled, and absorbed through the skin. 8 In non-pregnant populations, higher concentrations of certain phthalates are associated with adverse human health outcomes. For example, higher concentrations of mono-n-butyl phthalate (MBP), mono-benzyl phthalate (MBzP), and mono-(3-carboxypropyl) phthalate (MCPP) are associated with diabetes in non-pregnant women. [10] [11] [12] Higher concentrations of MBP, mono-octyl phthalate, and di-(2-ethylhexyl) phthalate (DEHP) are associated with an increased odds of endometriosis and fibroids in women. [13] [14] [15] [16] Of interest, data from a non-pregnant population suggest that there are both sex and racial/ethnic differences in urinary phthalate metabolite concentrations, with women and non-whites having higher concentrations of a variety of phthalate metabolites, including MBP, mono-ethyl phthalate (MEP), mono-isobutyl phthalate (MiBP), and MBzP. 17, 18 Although studies have shown higher concentrations of many phthalates in non-Hispanic black and Hispanic US populations, little is known about whether these population subgroups have higher levels during pregnancy. Characterizing the patterns of exposure by race/ethnicity could provide needed information to identify high-risk subgroups, particularly given the growing body of evidence that suggest that phthalates may be associated with adverse pregnancy and child health outcomes. For example, a recent study found that pregnant women with higher urinary concentrations of MEHP, as well as MBzP, MBP, and MCPP, had an increased odds of spontaneous preterm birth. 4, 19 Another study found associations between mono-methyl phthalate (MMP) and DEHP metabolites with intrauterine growth restriction. 20 In the offspring, in utero exposure to higher levels of DEHP and butyl-benzyl phthalate were associated with changes in reproductive development, eczema, and allergic conditions, 5, 21 respectively. Several studies have also shown an association between phthalates, namely, metabolites of DEHP and di-isobutyl phthalate (DiBP), with adverse neurobehavioral outcomes in children. [22] [23] [24] Although previous studies have evaluated the variability of phthalate levels across pregnancy, 25, 26 no study has characterized phthalate metabolite levels by race/ethnicity in a multi-racial population of pregnant women.
In this study, we evaluated the change in phthalate metabolite levels in pregnant women across early, mid, and late pregnancy by race/ethnicity. We compared the mean phthalate levels in second and third trimesters of pregnancy with baseline measures from first trimester. Given racial/ethnic disparities in certain pregnancy and child health outcomes, such as gestational diabetes and small-for-gestational age, understanding variations in phthalate metabolite levels across pregnancy in a diverse population may provide needed information about high-exposure and high-risk groups. Furthermore, this study provides needed information about certain high-exposure populations with details on potential sensitive and critical windows across pregnancy. As such, the purpose of this study was to provide data on phthalate metabolite concentrations across the full-course of pregnancy by an important predictor of pregnancy and infant/child health outcomes-race/ethnicity.
METHODS

Study Population
The Lifecodes pregnancy cohort is an ongoing study of women who delivered at Brigham and Women's Hospital (Boston, MA, USA). Starting in 2006, women were recruited into the cohort during the first trimester of pregnancy (at a median of 10 weeks gestation). Blood and urine samples were collected at four different study visits, and study participants completed a demographic questionnaire querying sociodemographic and lifestyle factors. Blood plasma and serum were stored at − 20°C, and urine was stored at − 80°C.
In 2011, a nested case-control study was initiated among women who delivered between 2006 and 2008 to assess the association between phthalate exposure and preterm birth in this study population. Details regarding this nested case-control study are presented elsewhere. 4 We included women with term pregnancies (437 weeks) to ensure the ability to assess changes in phthalate metabolite concentrations by race/ethnicity from early to late pregnancy. From those women who were originally selected as controls delivering at term (437 weeks gestation; n = 350 women), we utilized existing data from completed questionnaires and urinary phthalate metabolite levels from the four pregnancy time points. We selected term births, as they represent women who were able to complete pregnancy and had the greatest number of urine samples across pregnancy, in order to evaluate changes in urinary phthalate metabolites across the entire pregnancy. All women provided informed consent. This study was approved by the Partners Human Subjects Committee at Brigham and Women's Hospital, as well as the University of Michigan's Health Sciences Institutional Review Board.
Urinary Phthalate Metabolites
Phthalate metabolites were measured in spot urine samples collected at four time points across pregnancy. Urine samples were collected at visits occurring at the following median gestation weeks: visit 1: 9.9 weeks gestation (8-10 weeks); visit 2: 17.9 weeks gestation (16-18 weeks); visit 3: 26.1 weeks gestation (22-26 weeks); and visit 4: 35.3 weeks gestation (33-36 weeks) . Of the 350 possible samples at each time point, 99% were available at visit 1; 87% were available at visit 2; 86% were available at visit 3, and 90% were available at visit 4. Urine was collected in low-density polyethylene containers. These samples were stored at 4°C until processed within 3 h of collection time. Upon processing, samples were divided into polypropylene aliquot tubes (Fisher Brand 2 mL cryogenic vial (cat. no. 10-500-26) with high-density polyethylene caps). Urines were stored in these aliquot tubes at − 80°C until the time of urinary phthalate metabolite analysis.
We measured MBP, MEP, MiBP, MBzP, MCPP, MEHP, mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP), and mono-2-ethyl-5-oxohexyl phthalate (MEOHP). The latter four are metabolites of DEHP. Because of their high correlation, we created two summary measures of DEHP based on the molar sum of the DEHP metabolites. These were assessed by NSF International (Ann Arbor, MI, USA) using the Centers for Disease Control and Prevention protocol described elsewhere. 4, 27 In brief, phthalate metabolites were converted from their glucoronidated form by enzymatic deconjugation followed by solid-phase extraction and separation using high-performance liquid chromatography. Tandem mass spectrometry was used for detection with limits ranging in the low nanogram per milliliter levels. The first summary measure included all four metabolites (MEHHP, MECPP, MEOHP, and MEHP) and the second included the three oxidative metabolites excluding MEHP. 25 When levels were below the limit of detection, we assigned a value of the limit of detection divided by the square root of 2. 28 To account for urine concentration, we adjusted for specific gravity (SG) in this analysis using the following formula: P c = P((1.015 − 1)/SG − 1), where P c represents the SG-adjusted concentration, P represents the measured urinary concentration, SG represents the SG for the individual sample, and 1.015 is the median SG overall samples. 4, 29 Urine samples with SG41.04 were excluded (three urine samples were excluded). 30 
Race/Ethnicity
At study entry (8-10 weeks gestation), women completed a baseline questionnaire, which collected information on a variety of sociodemographic factors. Women responded to a two-part question: (1) "What race do you consider yourself: Black, White, South Asian, East Asian, Native American/Pacific Islander, More than one race, Other" and (2) "Do you consider yourself to have a Hispanic or Latino background?: Yes or No." Women were able to select more than one category for race. Women who selected "Other", "More than one race", or who marked more than one racial category were categorized as "Other". Women who selected "Yes" for the second question regarding Hispanic or Latino ethnicity were categorized as Hispanic, regardless of the race they selected in the first question. Because of the small numbers, we collapsed "South Asian" and "East Asian" into a single category of "Asian". Given few Native American/Pacific Islanders in our study population, women selecting this racial category were categorized as "Other". Thus the final categories used in this analysis were non-Hispanic white, non-Hispanic black, Hispanic, Asian, and other.
Statistical Analysis
For all analyses, we used log 10 -transformed SG-adjusted urinary phthalate metabolite concentrations. First, we evaluated characteristics of the study population stratified by race/ethnicity, calculating mean and SDs for continuous variables and percentages for categorical variables. Second, we calculated the geometric means of each phthalate metabolite at baseline (median 10 weeks) for the overall population, as well as for each racial/ ethnic group. We used ANOVA to determine whether baseline levels significantly differed by race/ethnicity. Third, to capture the overall change in phthalate exposure during pregnancy, we used linear mixed models with a random intercept to estimate the percent change and 95% confidence intervals in phthalate metabolite levels comparing each later pregnancy measure (i.e., 16-18, 22-26, and 33-35 weeks) to the baseline measure at 8-10 weeks gestation. Percent change and 95% confidence intervals were calculated for the overall population, as well as for each racial/ethnic group. We constructed two models: model (1) unadjusted model and model (2) fully-adjusted for maternal age, education, weight at time-specific gestational age, alcohol use, and smoking status. These sociodemographic and lifestyle factors were selected based on the limited information collected by questionnaire data in this cohort. We had an a priori hypothesis that these factors might be potential confounders of the association between race/ ethnicity and phthalate metabolite concentrations. We also plotted the adjusted phthalate metabolite concentrations stratified by race/ethnicity. Multivariable-adjusted least-squares geometric means of each phthalate metabolite were calculated by race/ethnicity at each time point in pregnancy (8-10 weeks, 16-18 weeks, 22-26 weeks, and 33-35 weeks gestation), and plotted. We calculated percentage of variability in baseline phthalate metabolite concentrations explained by each variable by comparing the R-squared between the models with and without the variable of interest. A previous study has evaluated reproducibility of phthalate metabolite levels in this pregnancy cohort, with low-to-moderate reproducibility. 29 
RESULTS
In Table 1 , we present baseline (8-10 weeks gestation) study population characteristics stratified by race/ethnicity. Women were of a diverse background with 16% African-American, 14% Hispanic, 5% Asian, and 59% white. The mean age was 31.9 years (SD = 5.5) for the overall study population of women with term births, with the baseline BMI being 25.9 kg/m 2 (SD = 5.7). A large proportion of the population was college graduates or higher (43.1%). Most women were never smokers (94.6%) and did not currently use alcohol during pregnancy (94.6%).
Sociodemographic factors that differed by race/ethnicity included maternal age, BMI, weight, and education (P o 0.0001). Specifically, white women were older, leaner, and a greater proportion had a college degree or higher. African-Americans had the highest mean first trimester weight at 78 kg. Hispanics were the youngest with a mean age of 27 years. Table 2 presents SG-adjusted geometric means and 25th and 75th percentiles for baseline urinary phthalate metabolite levels for the overall population and by race/ethnicity. With the exception of the DEHP metabolites (i.e., MEHP, MEHHP, MEOHP, and MECPP), all baseline phthalate metabolites varied significantly by race/ethnicity, with the highest levels being among non-Hispanic blacks, Hispanics, and those who selected 'Other' race/ethnicity. In fact, non-Hispanic blacks had a baseline SG-adjusted geometric mean MEP level of 286.0 μg/l compared with 98.7 μg/l for whites. Also, SG-adjusted geometric means for MBzP were considerably higher for Hispanics and non-Hispanic blacks compared with whites: 11.6 μg/l, 10.2 μg/l, and 5.4 μg/l, respectively.
Change in Phthalate Metabolites Across Full-Term Pregnancies-Overall Population In Table 3 , we present the percent change in pregnancy phthalate metabolite concentrations for the overall study population. Although phthalate metabolite levels did not significantly change from 8-10 weeks to 16-18 weeks for any of the measured metabolites, when comparing 8-10 weeks to 22-26 weeks we saw significant changes in MCPP and the DEHP metabolites. In fact, there was a 16.0% decrease (95% CI: − 27.4, − 2.8) in MCPP after adjustment for age, race/ethnicity, education, period-specific weight, alcohol use, and smoking status. For the total DEHP metabolites, after full adjustment, there was a 30.6% decrease (95% CI: − 40.9, − 18.4), which was similar for the oxidative metabolites for DEHP. When comparing the change from 8-10 weeks to levels at 33-35 weeks gestation, there was no longer a significant change in MCPP, but MEHP, a metabolite of DEHP, continued to show a decrease compared with baseline (fully adjusted: − 20.2%; 95% CI: − 33.2, − 4.6). MiBP at 33-35 weeks had an 18.6% increase (95% CI: 7.8, 30.5) after adjustment for weight. MBzP also showed a significant increase (crude: 12.1%; Race, phthalates, and pregnancy95% CI: 0.7, 24.8), but this did not hold after full adjustment (fully adjusted: 9.0; 95% CI: − 4.0, 23.7).
Change in Phthalate Metabolites Across Full-term Pregnancies by
Race/Ethnicity In Figure 1 (panels a-h), we present fully-adjusted least squares geometric means of each phthalate metabolite by race/ethnicity. (see Supplementary Tables S1-S3 for corresponding estimates of percent change). At all time points across pregnancy, nonHispanic blacks had the highest concentrations of MCPP and the DEHP metabolites compared with any other racial/ethnic groups. Whereas Hispanics had higher levels of MBP and MBzP compared with other racial/ethnic groups at all time points in pregnancy.
Concentrations of MEP and MiBP were higher in non-Hispanic blacks and Hispanics compared with whites across all pregnancy time points. Race/ethnicity explained the greatest variability in MEP and MBzP (10.1% and 10.7%, respectively). It explained little of the variability in ∑DEHP (0.7%). Other variables failed to explain this degree of variability after accounting for race/ethnicity. Patterns across pregnancy differed for each phthalate metabolite, with MEP and MCPP having statistically significant differences by race/ethnicity (P for interaction for MEP = 0.04 and P for interaction for MCPP = 0.02). Levels of MEP decreased in second and third trimesters for Hispanic women but remained relatively constant and high for non-Hispanic black women throughout pregnancy. White women had low levels of this phthalate metabolite, which remained fairly constant throughout pregnancy.
MCPP levels in non-Hispanic blacks were higher than in whites and Hispanics for the first two trimesters of pregnancy and decreased substantially at 22-26 weeks and 33-35 weeks gestation. On the other hand, Hispanics had a slight increase across pregnancy, with levels being higher than non-Hispanic blacks by third trimester. Whites maintained relatively constant levels of this phthalate metabolite. Interestingly, MiBP increased during pregnancy for all racial/ethnic groups. On the other hand, ∑DEHP modestly declined across pregnancy until late second trimester and then slightly increased by 33-35 weeks gestation. However, racial/ethnic differences in the patterns of these phthalates across pregnancy did not reach statistical significance.
DISCUSSION
We found significant racial/ethnic differences in the change in certain phthalate metabolite concentrations across full-term pregnancies. Phthalate metabolite concentrations were higher in non-Hispanic black and Hispanic women across all pregnancy time points. In the overall population, levels of MCPP and ∑DEHP metabolites significantly decreased, whereas levels of MiBP increased across pregnancy. Patterns of MEP and MCPP significantly differed by race/ethnicity across pregnancy, with decreasing levels in mid-pregnancy in non-Hispanic black and Hispanic women for MCPP and MEP, respectively. However, levels of these and all other phthalate metabolites remained higher among nonwhites. During sensitive and critical windows of time, higher exposure to certain phthalates could increase the risk of a number Values are the percentage of change (95% CI). a Adjusted for age (o25, 25-o30, 30-o35, 35-o40, 4-40), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, Asian, unknown/other), education (high school or less, technical school, some college, college graduate or higher), period-specific weight (continuous), alcohol drinking (yes, no), and smoking (current, past, never).
of maternal and child health outcomes. Given that certain racial/ethnic groups appear to be more highly exposed across pregnancy, these populations may be particularly vulnerable.
Racial/ethnic differences in urinary phthalate metabolite concentrations have been evaluated in a non-pregnant population comprised of a representative sample of the U.S. population participating in the National Health and Nutrition Examination Survey between 1999 and 2008. 17, 18 In non-pregnant populations, concentrations were higher in non-whites for most phthalate metabolites. 10, 18 When comparing our study of pregnant women to this non-pregnant population, levels of MBP were higher in pregnant non-Hispanic blacks and Hispanics participating in the present study. 18 Urinary concentrations of MiBP and MBzP were also higher in our population of pregnant women, regardless of race/ethnicity relative to the non-pregnant NHANES population. 18 MEP was lower in pregnant white women participating in our pregnancy cohort but higher in pregnant non-Hispanic black and Hispanic women participating in our pregnancy cohort. Another study evaluated overall phthalate metabolite concentrations in pregnant women. Specifically, Woodruff et al. 31 compared pregnant versus non-pregnant women who participated in NHANES 2003-2004, which showed lower levels among pregnant women for MBP, MEP, and MiBP but slightly higher levels of MBzP compared with non-pregnant women participating in NHANES. Urinary phthalate metabolite concentrations differed between our population and NHANES pregnant women from this earlier time period (NHANES 2003 (NHANES -2004 . 31 Our overall population of pregnant women had lower levels of MBzP and MEP and higher levels of MiBP compared with pregnant women in NHANES 2003-2004. 31 However, NHANES 2003-2004 levels of MEP were similar to that of our non-Hispanic black and Hispanic pregnant population. 31 When evaluating other studies that examined phthalate levels in pregnant populations, we found levels of MEP and MBP to be lower in our overall pregnant population compared with a study of black and Dominican women measured between 2001 and 2006. 27 Levels were similar for MiBP in blacks and Hispanics and substantially lower for MBzP. 27 Differences in phthalate metabolite levels across these populations could be attributed to differences in laboratories across the various studies of pregnant women or changes in the use of certain phthalates over time. In fact, a recent study found decreasing levels of many phthalate metabolites, with an increase in the use of DiBP when evaluating a subset of NHANES participants between 2001 and 2010. 32 Reasons for racial/ethnic variations in urinary phthalate metabolite concentrations are likely due to differences in exposure to phthalate containing consumer products. One study found associations between self-reported personal care product use during pregnancy from a short questionnaire and phthalate metabolite concentrations in pregnant women. 33 Another study of pregnant women suggested that differences in the use of perfumes could contribute to racial/ethnic variations in levels of MEP, as 45% of blacks and 41% of Dominicans used perfumes, with many using perfumes daily. 26 A different study of predominantly pregnant white women found a prevalence of perfume use of 31%. 33 Another alternative is that certain consumer products are predominantly used by one specific racial/ethnic group. In 2004, Silva et al. 17 posited that higher levels in non-pregnant, non-Hispanic blacks could be attributed to the use of certain types of hair products. Interestingly, a previous study found that non-pregnant black women were more likely to use hair products containing endocrine-disrupting chemicals based on hair product labels compared with white women (~50% of non-Hispanic black women compared with~8% of white women). 34 However, phthalates are not required to be listed on the labels of personal care or other consumer products. Other possible sources of phthalate exposure based on lifestyle factors could be through nail polish use and higher intake of packaged food items in certain populations. Little is known about racial/ethnic differences in patterns of consumer product use related to phthalate exposure. Future studies will need to evaluate sources of exposure in a racially/ethnically diverse population accounting for product types that may differ across racial/ethnic groups to determine whether patterns of consumer product use could partially explain the significant differences for certain phthalate metabolite levels in pregnant women.
Higher concentrations of certain phthalate metabolites in utero among non-Hispanic black and Hispanic women may contribute to a portion of the racial/ethnic differences in pregnancy outcomes. For example, a recent study found associations between higher in utero exposure to MMP and DEHP and intrauterine growth restriction. 20 Interestingly, a greater proportion of non-Hispanic black women have infants born small-forgestational age compared with other racial/ethnic groups, 35 which is likely related to a host of factors but could also be partly due to higher phthalate exposure in utero. Higher phthalate levels could also explain some portion of racial/ethnic differences in maternal health outcomes. A recent study, using the same population as the present study, found an association between higher MBP, MBzP, MCPP, and MEHP and an increased risk of spontaneous preterm birth. 4 Non-Hispanic black women have a significantly higher preterm birth rate than white women. 36 Future studies will need to confirm racial/ethnic differences in phthalate metabolite concentrations, as well as determine whether these differences could contribute to racial/ethnic disparities in poor infant or maternal health outcomes. If associations are found, interventions focusing on changing the use of certain products known to be associated with increased exposure of these chemicals could reduce phthalate exposure in pregnancy, 21, 33 with implications on maternal and child health.
This study has several limitations. First, we only evaluated women who had term births in order to assess racial/ethnic differences in the change in urinary phthalate metabolite concentrations across pregnancy. A previous study showed an association between higher phthalate metabolite concentrations and preterm birth in this population. 4 As such, we possibly have a restricted subset of the population that is generally healthier and has somewhat lower phthalate metabolite concentrations than all pregnant women, which could possibly attenuate some of the racial/ethnic differences in certain phthalate metabolite concentrations. Small sample sizes among our preterm births limited our ability to evaluate the question of racial/ethnic differences in urinary phthalate metabolite concentrations, yet we still found significant racial/ethnic differences for certain phthalate metabolites. Furthermore, we were able to document the change in phthalate metabolite concentrations across the full-course of pregnancy, including late pregnancy in this diverse study population. Second, we did not have data on diet or lifestyle factors, including consumer product use for the study population. As major sources of phthalate exposure, 8, 33, 37 data on these factors could provide insight into reasons for differences across racial/ethnic groups based on behavior patterns. Future studies will need to evaluate whether diet or lifestyle factors explain some of the racial/ethnic differences found in the present study. Third, our stratified analyses are based on a somewhat small subset of non-Hispanic black and Hispanic women. We could not evaluate Asian women in the longitudinal analysis across pregnancy owing to small numbers. However, we did find statistically significant associations between racial/ethnic groups that are not likely due to chance alone. We also cannot rule out the possibility of differences in phthalate metabolism that could impact urinary concentrations based on geographic heritage, as well as a variety of other social and environmental factors.
Despite these limitations, this study has several strengths. First, we measured phthalate metabolite concentrations across four time points in pregnancy, with the majority of women in the population having data on all four time points. Second, we were able to assess patterns of several different phthalate metabolite concentrations, as well as the ΣDEHP metabolites in three different racial/ethnic groups. Third, we evaluated the percent change in phthalate metabolites for the overall population and stratified by race/ ethnicity controlling for potential confounders. As such, we were able to evaluate patterns and changes in phthalate metabolites during early, mid, and late pregnancy to determine whether racial/ ethnic differences in these environmental toxicants existed.
In conclusion, we found certain phthalate metabolite concentrations to vary by race/ethnicity across pregnancy. Concentrations of MBP, MEP, MiBP, and MBzP were significantly higher among non-Hispanic blacks and Hispanics during early first trimester, with significant changes in MiBP, MCPP, and the DEHP metabolites across pregnancy for the overall population. Across pregnancy, MEP and MCPP varied significantly by race/ethnicity, with non-Hispanic black and Hispanic women having substantially higher levels compared with non-Hispanic white women. Concentrations of MEP decreased for non-Hispanic blacks in mid-to-late pregnancy but remained steady for Hispanic women.
Non-Hispanic blacks had substantially higher concentrations of MCPP compared with other racial/ethnic groups, with concentrations decreasing in mid-pregnancy but not reaching the lower concentrations of non-Hispanic white or Hispanic women. These data suggest that certain phthalate metabolite concentrations are higher in non-whites (i.e., MBP, MEP, MiBP, MBzP, and MCPP). These phthalate metabolites have been shown to be associated with a variety of adverse human health outcomes, including an increased risk of diabetes and hyperglycemia in non-pregnant women and adolescents. Of particular interest is that increases and decreases of some of these chemicals may impact important critical and sensitive windows during pregnancy, which could subsequently affect maternal and child health outcomes. If higher concentrations of these chemicals are found to be associated with adverse pregnancy and child health outcomes, non-Hispanic black and Hispanic pregnant women may benefit from interventions to decrease certain phthalate exposures during pregnancy to improve their health and the health of their offspring.
